Abstract | BACKGROUND: METHODS: This review is based on publications that were retrieved from Medline (via PubMed) and The Cochrane Library. The clinical database ClinicalTrials.gov. was also considered. RESULTS: CONCLUSION: The polypill can be considered as an alternative to polypharmacy after a risk-benefit assessment, especially in non-adherent patients. Ongoing studies are investigating the effect of the polypill on cardiovascular events. Current polypills are limited by the lack of sufficient dosages of the individual components to avoid overtreatment and undertreatment at the individual treatment level.
|
Authors | P Bramlage, W März, D Westermann, B Weisser, J H Wirtz, U Zeymer, P Baumgart, G van Mark, U Laufs, B K Krämer, T Unger |
Journal | Herz
(Herz)
Vol. 43
Issue 3
Pg. 246-257
(May 2018)
ISSN: 1615-6692 [Electronic] Germany |
Vernacular Title | Management verschiedener kardiovaskulärer Risikofaktoren mit einem Kombinationspräparat („Polypill“). |
PMID | 28341983
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antihypertensive Agents
- Cardiovascular Agents
- Drug Combinations
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Tablets
|
Topics |
- Antihypertensive Agents
- Cardiovascular Agents
- Cardiovascular Diseases
- Drug Combinations
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Risk Factors
- Tablets
|